Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.

abstract：:There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

journal_title：Leukemia & lymphoma

authors： Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

更新日期：2012-02-01 00:00:00

abstract：:Primary effusion lymphoma (PEL) is a recently described rare type of non-Hodgkin's lymphoma occurring almost exclusively in HIV infected people. Human herpesvirus 8 (HHV-8), has been linked with PEL, and a causative relationship has been suggested. In the vast majority of PEL cases Epstein-Barr virus (EBV) has been fo...

journal_title：Leukemia & lymphoma

authors： Klepfish A,Sarid R,Shtalrid M,Shvidel L,Berrebi A,Schattner A

更新日期：2001-04-01 00:00:00

abstract：:EBER in situ hybridization (EBER) and LMP-1 immunohistochemistry (LMP-1) are widely used for identifying Epstein-Barr virus (EBV) within tumor cells of Hodgkin lymphoma (HL), but measurement error has never been formally evaluated. To determine assay reliability, 40 HL tumors with known EBV status were stained for bot...

journal_title：Leukemia & lymphoma

authors： Glaser SL,Gulley ML,Borowitz MJ,Craig FE,Mann RB,Stewart SL,Shema SJ,Ambinder RF

更新日期：2004-03-01 00:00:00

abstract：:The quinazoline antifolate N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl)-L-glutamic acid (ZD1694; Tomudex) is a potent inhibitor of thymidylate synthase and causes cell death through disruption of DNA synthesis and repair by blocking the obligatory thymidine nucleotide synthesis....

journal_title：Leukemia & lymphoma

authors： Ek O,Reaman GH,Crankshaw DL,Chelstrom LM,Myers DE,Uckun FM

更新日期：1998-02-01 00:00:00

abstract：:Pixantrone is a potentially more effective, less cardiotoxic alternative to doxorubicin for patients with aggressive non-Hodgkin lymphoma (aNHL). This phase I/II non-comparative study evaluated pixantrone in place of doxorubicin in the standard CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone),...

journal_title：Leukemia & lymphoma

authors： Borchmann P,Herbrecht R,Wilhelm M,Morschhauser F,Hess G,Cernohous P,Veals SA,Singer JW,Engert A

更新日期：2011-04-01 00:00:00

abstract：:Since etoposide interacts with the nuclear enzyme topoisomerase II, the drug concentrations in the malignant cells during chemotherapy may have clinical correlates. Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug. The p...

journal_title：Leukemia & lymphoma

authors： Liliemark EK,Liliemark J,Pettersson B,Gruber A,Björkholm M,Peterson C

更新日期：1993-07-01 00:00:00

abstract：:Follicular lymphoma (FL) is characterized by an initial response to treatment with inevitable relapse. We evaluated chemoimmunotherapy resistance (CIR resistance) including transformation. We identified patients who received rituximab combination therapy for symptomatic FL. CIR resistance was defined as disease progre...

journal_title：Leukemia & lymphoma

authors： Mozessohn L,Cheung MC,Crump M,Buckstein R,Berinstein N,Imrie K,Kuruvilla J,Piliotis E,Kukreti V

更新日期：2014-11-01 00:00:00

abstract：:In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyro...

journal_title：Leukemia & lymphoma

authors： Sarkar S,Svoboda M,de Beaumont R,Freedman AS

更新日期：2002-08-01 00:00:00

abstract：:One hundred and ninety-six untreated de novo acute myeloid leukemia (AML) patients were treated with homoharringtonine + cytosine arabinoside (HA) based induction therapy composed of three chemotherapeutic drugs (HAD/M, D-daunorubicin-DNR, M-mitozantrone-MTZ) used in our hospital for the past 12 years. The patient pop...

journal_title：Leukemia & lymphoma

authors： Mi Y,Xue Y,Yu W,Liu S,Zhao Y,Meng Q,Bian S,Wang J

更新日期：2008-03-01 00:00:00

abstract：:This retrospectively collected laboratory-based surveillance data includes 575 healthcare-associated bloodstream infections (BSIs) in 350 patients with hematological malignancy in Tampere University Hospital, Finland, during 1999-2001 and 2005-2010. The most common underlying diseases were acute myelogenous leukemia (...

journal_title：Leukemia & lymphoma

authors： Åttman E,Aittoniemi J,Sinisalo M,Vuento R,Lyytikäinen O,Kärki T,Syrjänen J,Huttunen R

更新日期：2015-01-01 00:00:00

abstract：:This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

journal_title：Leukemia & lymphoma

authors： Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

更新日期：2018-08-01 00:00:00

abstract：:Vaginal bleeding during aplasia can induce transfusion support, infection and discomfort. Oral and intramuscular hormonotherapy can be toxic and/or difficult to manage (mucositis). This single-center pilot study evaluated the efficacy and safety of leuprorelin (L) in preventing heavy vaginal bleeding in 20 nonmenopaus...

journal_title：Leukemia & lymphoma

authors： Lhommé C,Brault P,Bourhis JH,Pautier P,Dohollou N,Dietrich PY,Akbar-Zadeh G,Lucas C,Pico JL,Hayat M

更新日期：2001-09-01 00:00:00

abstract：:This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma. During phase I, panobinostat was given daily on Monday/Wednesday/Friday starting one week prior to Cycle 1 (C1) of ICE and during two weeks of C1-2 of ICE...

journal_title：Leukemia & lymphoma

authors： Hu B,Younes A,Westin JR,Turturro F,Claret L,Feng L,Fowler N,Neelapu S,Romaguera J,Hagemeister FB,Rodriguez MA,Samaniego F,Fayad LE,Copeland AR,Nastoupil LJ,Nieto Y,Fanale MA,Oki Y

更新日期：2018-04-01 00:00:00

abstract：:Tyrosine kinase inhibitors (TKIs) are teratogenic. Chronic myeloid leukemia (CML) is increasingly identified in younger patients who wish to conceive, the management of CML during pregnancy is challenging. We reviewed 51 pregnancies involving 37 patients (30 women, 10 with >1 pregnancy and 7 men) who were either diagn...

journal_title：Leukemia & lymphoma

authors： Assi R,Kantarjian H,Keating M,Pemmaraju N,Verstovsek S,Garcia-Manero G,Ravandi F,Borthakur G,Dahl J,Jabbour E,Cortes JE

更新日期：2020-12-07 00:00:00

abstract：:We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before tr...

journal_title：Leukemia & lymphoma

authors： Luminari S,Cesaretti M,Tomasello C,Guida A,Bagni B,Merli F,Postiglione R,Mangone L,Versari A,Re F,De Lisi V,Ruffini L,Ferretti S,Cuneo A,Federico M

更新日期：2011-09-01 00:00:00

abstract：:The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...

journal_title：Leukemia & lymphoma

authors： Cohen KA,Liu TF,Cline JM,Wagner JD,Hall PD,Frankel AE

更新日期：2004-08-01 00:00:00

abstract：:Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to R...

journal_title：Leukemia & lymphoma

authors： Janikova A,Bortlicek Z,Campr V,Kopalova N,Benesova K,Hamouzova J,Belada D,Prochazka V,Pytlik R,Vokurka S,Pirnos J,Duras J,Mocikova H,Mayer J,Trneny M

更新日期：2016-05-01 00:00:00

abstract：:We review results of intensive chemotherapy (IC) obtained in myelodysplastic syndromes (MDS). Overall, the complete remission (CR) rates and median CR duration obtained with IC are low in MDS, especially when compared to results obtained in de novo AML treated with the same chemotherapy regimens; very few MDS patients...

journal_title：Leukemia & lymphoma

authors： Fenaux P,Preudhomme C,Hebbar M

更新日期：1992-09-01 00:00:00

abstract：:Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in rela...

journal_title：Leukemia & lymphoma

authors： Sasse S,Alram M,Müller H,Smardová L,Metzner B,Doehner H,Fischer T,Niederwieser DW,Schmitz N,Schäfer-Eckart K,Raemaekers JM,Schmalz O,Tresckow BV,Engert A,Borchmann P

更新日期：2016-05-01 00:00:00

abstract：:Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

journal_title：Leukemia & lymphoma

authors： Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

更新日期：2021-01-11 00:00:00

abstract：:Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding V(H) and V(L)...

journal_title：Leukemia & lymphoma

authors： Stevenson FK,King A,Ottensmeier CH

更新日期：2003-01-01 00:00:00

abstract：:Permanently established human cell lines can produce several retroviruses. It is important to routinely test such cell lines for human T cell lymphotropic virus (HTLV) type I and II, and for human immunodeficiency virus (HIV) type 1 and 2 in order to exclude any potential biohazard from cell lines producing human retr...

journal_title：Leukemia & lymphoma

authors： Häne BG,Drexler HG

更新日期：1993-10-01 00:00:00

abstract：:Long-term survivors of childhood leukemia are at risk for neurocognitive impairment, although the neurophysiological basis is not well understood. The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemothe...

journal_title：Leukemia & lymphoma

authors： Krull KR,Hockenberry MJ,Miketova P,Carey M,Moore IM

更新日期：2013-03-01 00:00:00

abstract：:We and others previously demonstrated that human multiple myeloma (MM) cells express CD40 and have an active CD40-growth regulatory pathway. This study characterizes the growth outcome of soluble (gp39) or membrane-bound recombinant human CD40-ligand (rCD40L) and its relationship with Fas-dependent apoptosis. Contrary...

journal_title：Leukemia & lymphoma

authors： Tong AW,Seamour B,Chen J,Su D,Ordonez G,Frase L,Netto G,Stone MJ

更新日期：2000-02-01 00:00:00

abstract：:Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

journal_title：Leukemia & lymphoma

authors： Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

更新日期：2019-07-01 00:00:00

abstract：:We report a case of Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD) which developed after chemotherapy for hemophagocytic lymphohistiocytosis (HLH), who had no history of immunodeficiency or familial X-linked LPD. In HLH, the presence of EBV in T-cells was confirmed by a combination of in situ h...

journal_title：Leukemia & lymphoma

authors： Suzumiya J,Ohshima K,Kanda M,Kumagawa M,Nagano M,Hirata M,Nawa Y,Tamura K,Kikuchi M

更新日期：2000-05-01 00:00:00

abstract：:Analysis of the microRNA transcriptome following dexa- methasone treatment of the acute lymphocytic leukemia (ALL) cell line RS4;11 showed a global down-regulation of microRNA levels. MIR17HG was rapidly down-regulated following treatment, with chromatin immunoprecipitation (ChIP) analysis demonstrating the promoter t...

journal_title：Leukemia & lymphoma

authors： Harada M,Pokrovskaja-Tamm K,Söderhäll S,Heyman M,Grander D,Corcoran M

更新日期：2012-10-01 00:00:00

abstract：:Leukemic lymphoblasts in B-lineage acute lymphoblastic leukemia (ALL) express morphologic, phenotypic and genotypic features which resemble those of B lymphocyte progenitors in normal bone marrow. Normal immature B cells and cells from most cases of B-lineage ALL rapidly die in vitro unless they are supported by bone ...

journal_title：Leukemia & lymphoma

authors： Campana D,Coustan-Smith E,Kumagai MA,Manabe A

更新日期：1994-05-01 00:00:00

abstract：:The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs. In order to investigate the biological consequences of treating CML cells with such drugs, we previously reported that the antioxidant sele...

journal_title：Leukemia & lymphoma

authors： Reinke EN,Bera S,Diamond AM

更新日期：2015-04-01 00:00:00

abstract：:Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years. Fifty-one percent had B symptoms and 51% serum elevated lactate dehydrogenase (LDH) levels. Eastern Cooperative Oncolo...

journal_title：Leukemia & lymphoma

authors： Broussais-Guillaumot F,Coso D,Belmecheri N,Ivanov V,Schiano de Collela JM,Aurran-Schleinitz T,Stoppa AM,Chetaille B,Xerri L,Esterni B,Blaise D,Bouabdallah R

更新日期：2013-11-01 00:00:00